Is Pharming Group N.V. (PHAR) a Buy, Sell, or Hold?
NASDAQ : PHAR
Pharming Group N.V.
$13.2 USD
-$0.2 (-1.49%)
- Volume
- 3.03K
- Average Volume
- 10.12K
- Market Capitalization
- $932.25M
- P/E Ratio
- 67.95
- Dividend Yield
- 0.00%
- Price Target
- $37.00
- Year High
- $21.34
- Year Low
- $9.54
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.63
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Fabrice Chouraqui |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | PHAR |
| CUSIP | 71716E105 |
| CIK | 0001828316 |
| Web | https://www.pharming.com |
| Phone | 31 71 524 7400 |
| Currency | USD |
| Employees | 407 |
| Country | NL |
Liquidity
| Debt-to-Equity Ratio | 0.43 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.63 |
| Quick Ratio | 2.06 |
| Cash Ratio | 0.47 |
Sales & Book Value
| Annual Sales | $376.13M |
| Price / Sales | 2.53 |
| Cash Flow | 0.70 |
| Price / Cash Flow | 18.02 |
| Price / Book | 3.66 |
Price Target and Rating
| Average Stock Price Forecast | $37.00 |
| High Stock Price Forecast | $40.00 |
| Low Stock Price Forecast | $37.00 |
| Forecast Upside/Downside | -64.32% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 2 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.04 |
| Trailing P/E Ratio | 67.95 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $2.85M |
| Net Margin | 3.37% |
| Pretax Margin | 5.42% |
| Return on Equity | 4.75% |
| Return on Assets | 2.55% |
Financials Score
| AltmanZ Score | 2.86 |
| Piotroski Score | 6.00 |
| Working Capital | 183.16M |
| Total Assets | 489.36M |
| Ebit | 31.93M |
| Market Cap | 825.05M |
| Total Liabilities | 220.41M |
Poll Results
About Pharming Group N.V. (NASDAQ:PHAR) Stock
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well a ... s an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
2026-06-04 01:00:00
If approved, Joenja will be the first approved treatment in the U. S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosingSeparate sNDA for lower weight pediatric patients planned for second half 2026 Leiden, the Netherlands, June 4, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.
2026-06-04 01:00:00
Pharming today announced that the U.S. FDA accepted its sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Pharming Group announces results of 2026 Annual General Meeting of Shareholders
2026-05-28 10:40:00
Pharming Group announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held on May 28, 2026.
Pharming Group Q1 Earnings Call Highlights
2026-05-08 16:03:05
Pharming Group NASDAQ: PHAR executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company's planned exit from certain non-U.S. markets, while Joenja continued to post strong growth and the company advanced regulatory and clinical milestones across its pipeline. Get Pharming Group alerts:Sign UpRUCONEST revenue declined as inventory dynamics played out CEO Fabrice Chouraqui said quarterly revenue fell primarily due to RUCONEST, a decline he said was “largely expected due to inventory drawdown at specialty pharmacy,” which the company previously discussed on its fourth-quarter 2025 call.
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
2026-05-07 12:41:18
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
2026-05-07 01:05:00
Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9 in New Orleans, LA.
2026-05-07 01:00:00
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026.
Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Declines By 15.5%
2026-04-19 04:50:42
Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR - Get Free Report) saw a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 12,882 shares, a decline of 15.5% from the March 15th total of 15,251 shares. Approximately 0.0% of the company's shares are sold short. Based
Frequently Asked Questions
-
What is the current Pharming Group N.V. (PHAR) stock price?
-
Pharming Group N.V.(NASDAQ:PHAR) stock price is $13.2 in the last trading session. During the trading session, PHAR stock reached the peak price of $21.34 while $9.535 was the lowest point it dropped to. The percentage change in PHAR stock occurred in the recent session was --1.49% while the dollar amount for the price change in PHAR stock was -$0.2.
-
PHAR's industry and sector of operation?
-
The NASDAQ listed PHAR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PHAR?
-
Bruno L. Giannetti | Consultant
Magnus Hansson | Medical Director
Ines Bernal | Chief People Officer
Michael Levitan | Vice President of Investor Relations & Corporate Communications
Ruud Van Outersterp | Chief Legal & Compliance Officer and Company Secretary -
How many employees does PHAR have?
-
Number of PHAR employees currently stands at 407. PHAR operates from Darwinweg 24, Leiden, ZH 2333 CR, NL.
-
Link for PHAR official website?
-
Official Website of PHAR is: https://www.pharming.com
-
How do I contact PHAR?
-
PHAR could be contacted at phone #31 71 524 7400 and can also be accessed through its website. PHAR operates from Darwinweg 24, Leiden, ZH 2333 CR, NL.
-
How many shares of PHAR are traded daily?
-
The average number of PHAR shares traded daily for last 3 months was 10.12K.
-
What is the market cap of PHAR currently?
-
The market value of PHAR currently stands at $932.25M with its latest stock price at $13.2